Viome Life Sciences Acquires Naring Health (including DiscernDX and Foodome)

Mapmygenome Acquires Microbiome Insights

May 29, 2025

Biotechnology

Mapmygenome, an AI-driven genomics company based in Hyderabad, India, has acquired Microbiome Insights, a Canadian microbiome sequencing and bioinformatics CRO with a CAP-accredited lab. The deal expands Mapmygenome's capabilities in metagenomics and bioinformatics and accelerates its geographic expansion into North America; financial terms were not disclosed.

ReShape Lifesciences and Vyome Therapeutics Complete Merger; Will Trade as Vyome Holdings (HIND)

August 14, 2025

Biotechnology

Vyome Therapeutics has closed its previously announced merger with ReShape Lifesciences, resulting in the combined public company Vyome Holdings which will begin trading on Nasdaq under the ticker HIND on August 15, 2025. Vyome, a Cambridge, Massachusetts-based clinical-stage company focused on immuno-inflammatory and rare disease therapeutics, will leverage the transaction to access public markets and advance its clinical-stage assets across the US-India innovation corridor.

Exact Sciences Acquires Paradigm Diagnostics and Viomics

March 3, 2020

Healthcare Services

Exact Sciences Corp. has completed the acquisitions of Phoenix-based Paradigm Diagnostics, Inc. and Viomics, Inc., adding a late-stage therapy selection genomic profiling test, a scalable clinical lab, and sequencing/biomarker discovery capabilities to its precision oncology portfolio. The deals (financial terms largely undisclosed in the company release) bring Paradigm and Viomics into Exact Sciences’ research and commercial platform to accelerate tissue- and blood-based advanced cancer diagnostics.

FemTec Health Acquires Nutrimedy

July 25, 2022

Healthcare Services

FemTec Health has acquired Nutrimedy, an evidence-based clinical nutrition platform that offers AI-enabled photo food recognition and support for 50+ medical conditions. The acquisition adds real-time, personalized nutrition and dietitian access to FemTec's Awesome Woman subscription suite, expanding the company's women's-health capabilities.

Ginkgo Bioworks Acquires Assets from Bitome

June 6, 2022

Biotechnology

Ginkgo Bioworks acquired certain assets from Bitome, a Boston-based developer of real-time metabolite monitoring technology, to integrate continuous metabolite monitoring into its cell engineering platform. The acquisition is intended to accelerate design-build-test-learn cycles and bioprocess optimization across Ginkgo’s portfolio of cell programs by providing real-time metabolic data and ML-driven insights.

Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio

December 11, 2024

Biotechnology

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and completed an oversubscribed $75 million financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners. The combined company will advance a pipeline built on epigenetic editing and non-viral, programmable in vivo delivery, with lead candidate CRMA-1001 targeted at chronic hepatitis B and D and a planned clinical trial application submission in 2025.